Company / Depreciation & Amortization
Myriad Genetics, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$53.7M
FY2025
5-year range
$52.7M / $62.8M
FY2021-FY2025
Trend
-12.3%
vs FY2024
Sector context
#30 of 163
Health Care
What the data says
Myriad Genetics, Inc.'s depreciation & amortization of $54M is higher than 82% of companies in the Health Care sector (FY2025). Depreciation & Amortization has fluctuated over the past 10 years, ranging from $27M in FY2016 to $72M in FY2020.
Based on SEC 10-K filings.
$54M in FY2025 with a 5-year CAGR of -5.7%. Top quartile in the Health Care sector.
Improved from $62M to $54M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +0.6%
- 5-Year CAGR
- -5.7%
- 10-Year CAGR
- -
Sector benchmark
-75.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -5.7%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 12.3% year-over-year.
- Ranks #30 out of 163 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $53.7M | -12.3% |
| FY2024 | $61.2M | -1.1% |
| FY2023 | $61.9M | +17.5% |
| FY2022 | $52.7M | -16.1% |
| FY2021 | $62.8M | -12.8% |
| FY2020 | $72.0M | +49.1% |
| FY2019 | $48.3M | -11.2% |
| FY2018 | $54.4M | +12.6% |
| FY2017 | $48.3M | +80.2% |
| FY2016 | $26.8M | +7.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026